---
title: "aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292765672.md"
description: "aTyr Pharma will present a subgroup analysis of the Phase 3 EFZO-FIT™ study on Efzofitimod for pulmonary sarcoidosis at the WASOG 2026 conference. This presentation highlights specific participant subsets to provide detailed insights into the drug's efficacy and performance in treating the condition."
datetime: "2026-07-15T12:02:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292765672.md)
  - [en](https://longbridge.com/en/news/292765672.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292765672.md)
generator: "portal-rs"
---

# aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026

aTyr Pharma will be showcasing a subgroup analysis of the Phase 3 EFZO-FIT™ study of Efzofitimod in pulmonary sarcoidosis at the World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG) conference in 2026. The study is paramount in evaluating the efficacy of Efzofitimod. This analysis will focus on specific subsets of participants, shedding light on the drug's impact. This event is significant as it provides detailed insights from the trial and aids in understanding the drug's performance in treating pulmonary sarcoidosis.

### Related Stocks

- [ATYR.US](https://longbridge.com/en/quote/ATYR.US.md)

## Related News & Research

- [Zevra Therapeutics presents long-term real-world MIPLYFFA data in Niemann-Pick type C at SSIEM 2026](https://longbridge.com/en/news/296905592.md)
- [Belite Bio to present Phase 3 DRAGON tinlarebant results in Stargardt disease at SOG congress](https://longbridge.com/en/news/296615069.md)
- [Ecopipam Priority Review Could Be A Game Changer For Teva Pharmaceutical Industries (TEVA)](https://longbridge.com/en/news/296688992.md)
- [AC Immune reports positive interim Phase 1 data for NLRP3 inhibitor ACI-19764](https://longbridge.com/en/news/296478492.md)
- [Harrow’s Iheezo Cuts Eye-Injection Discomfort by More Than Half](https://longbridge.com/en/news/296638124.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**